Latest papers

Past, present, and future of Japanese encephalitis.

Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51

Immune responses of recombinant adenoviruses expressing immunodominant epitopes against Japanese encephalitis virus.

Change in Japanese encephalitis virus distribution, Thailand.

IC51: a new investigational Japanese encephalitis vaccine. Dr Christoph Klade speaks to Duc Le, editor.

Statement on protection against Japanese encephalitis. An Advisory Committee Statement (ACS).

Cost-effectiveness of Japanese encephalitis (JE) immunization in Bali, Indonesia.

Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine.

Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study.

Safety of flavivirus chimeric vaccines: answer to Ishikawa et al. [Vaccine 26 (22) (2008) 2772-2781].

Japanese encephalitis vaccine in travelers.

Long-term stability of Vero cell-derived inactivated Japanese encephalitis vaccine prepared using serum-free medium.

Construction and evaluation of a chimeric pseudoinfectious virus vaccine to prevent Japanese encephalitis

Japanese encephalitis vaccines--needs, flaws and achievements.

Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants.

Vero cell-derived inactivated West Nile (WN) vaccine induces protective immunity against lethal WN virus infection in mice and shows a facilitated neutralizing antibody response in mice previously immunized with Japanese encephalitis vaccine.

Bursin as an adjuvant is a potent enhancer of immune response in mice immunized with the JEV subunit vaccine.

A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: immunogenicity and anamnestic responses.

Effect of genomic variation in the challenge virus on the neutralization titres of recipients of inactivated JE vaccines--report of a collaborative study on PRNT50 assays for Japanese encephalitis virus (JE) antibodies.

Novel strategy for treatment of Japanese encephalitis using arctigenin, a plant lignan.